NO20055652L - Laktatinneholdende farmasoytisk preparat og anvendelse av dette - Google Patents

Laktatinneholdende farmasoytisk preparat og anvendelse av dette

Info

Publication number
NO20055652L
NO20055652L NO20055652A NO20055652A NO20055652L NO 20055652 L NO20055652 L NO 20055652L NO 20055652 A NO20055652 A NO 20055652A NO 20055652 A NO20055652 A NO 20055652A NO 20055652 L NO20055652 L NO 20055652L
Authority
NO
Norway
Prior art keywords
lactate
millimoles per
pharmaceutical preparation
liters
containing pharmaceutical
Prior art date
Application number
NO20055652A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055652D0 (no
Inventor
Xavier M Leverve
Mustafa Iqbal
Original Assignee
Innogene Kalbiotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd
Publication of NO20055652D0 publication Critical patent/NO20055652D0/no
Publication of NO20055652L publication Critical patent/NO20055652L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
NO20055652A 2003-05-01 2005-11-30 Laktatinneholdende farmasoytisk preparat og anvendelse av dette NO20055652L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01
PCT/SG2004/000066 WO2004096204A1 (en) 2003-05-01 2004-03-22 Lactate containing pharmaceutical composition and uses thereof

Publications (2)

Publication Number Publication Date
NO20055652D0 NO20055652D0 (no) 2005-11-30
NO20055652L true NO20055652L (no) 2006-02-01

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055652A NO20055652L (no) 2003-05-01 2005-11-30 Laktatinneholdende farmasoytisk preparat og anvendelse av dette

Country Status (31)

Country Link
US (1) US20080125488A1 (xx)
EP (2) EP1759695A1 (xx)
JP (1) JP5037937B2 (xx)
KR (1) KR101076059B1 (xx)
CN (1) CN1777416B (xx)
AR (1) AR043670A1 (xx)
AT (1) ATE340568T1 (xx)
AU (1) AU2004233904B2 (xx)
BR (1) BRPI0409867A (xx)
CA (1) CA2523740C (xx)
CY (1) CY1105880T1 (xx)
DE (1) DE602004002585T2 (xx)
DK (1) DK1617834T3 (xx)
EA (2) EA013846B1 (xx)
ES (1) ES2274438T3 (xx)
HK (1) HK1085942A1 (xx)
IL (1) IL171721A (xx)
MA (1) MA27845A1 (xx)
MX (1) MXPA05011532A (xx)
MY (1) MY140382A (xx)
NO (1) NO20055652L (xx)
NZ (1) NZ543201A (xx)
PL (1) PL1617834T3 (xx)
PT (1) PT1617834E (xx)
SG (1) SG160217A1 (xx)
SI (1) SI1617834T1 (xx)
TN (1) TNSN05275A1 (xx)
TW (1) TWI290045B (xx)
UA (1) UA86937C2 (xx)
WO (1) WO2004096204A1 (xx)
ZA (1) ZA200509684B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007371A4 (en) * 2006-04-03 2009-07-22 Innogene Kalbiotech Pte Ltd LACTAT AND CALCIUM-CONTAINED PHARMACEUTICAL COMPOSITION AND ITS USES
DK2142186T3 (da) 2007-03-30 2014-08-04 Laccure Ab Anvendelse af oligomerer af mælkesyre ved behandling af gynækologiske infektioner
WO2010111650A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
CN102497853B (zh) 2009-03-26 2018-03-23 普马特里克斯营业公司 治疗肺病的干粉配方与方法
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2812414C (en) 2010-09-29 2020-09-22 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
CA2872012C (en) 2012-05-08 2017-06-20 Aeromics, Llc New methods
DK2879524T3 (en) * 2012-08-01 2016-12-12 Purac Biochem Bv Laktatpulver and manufacturing method thereof
US9557334B2 (en) 2012-10-25 2017-01-31 Run Them Sweet Llc Formulations and methods to provide nutrition to human and other patients
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
EP2754356A1 (en) 2013-01-15 2014-07-16 Purac Biochem N.V. Improved nisin production process
EP2769630B1 (en) 2013-02-26 2016-04-27 Purac Biochem N.V. Improved nisin production process
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
WO2015069961A1 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel prodrug salts
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
PL3481216T5 (pl) 2016-07-07 2024-07-01 Dsm Ip Assets B.V. Sposób otrzymywania izolatu białka rzepakowego i otrzymany za jego pomocą izolat białka rzepakowego
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
EP3920846A4 (en) * 2019-02-06 2022-11-09 The Board and Trustees of the Leland Stanford Junior University BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY RESULTS
US20230113843A1 (en) * 2020-01-24 2023-04-13 Daniel Q. Barkey Compositions and methods for weight loss
KR20240134314A (ko) * 2021-12-16 2024-09-09 알베올러스 바이오, 인코포레이티드 만성 폐 질환의 치료를 위한 흡입가능한 또는 섭취가능한 락트산 조성물
CN116531358A (zh) * 2023-06-06 2023-08-04 中国医科大学附属第一医院 含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100677A (en) * 1985-12-18 1992-03-31 Veech Richard L Fluid therapy with various organic anions
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
US5702880A (en) * 1993-06-04 1997-12-30 Biotime, Inc. Blood substitute comprising 0-5 mM K+
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
UA86937C2 (ru) 2009-06-10
EA010948B1 (ru) 2008-12-30
EA200501675A1 (ru) 2006-06-30
SI1617834T1 (sl) 2007-02-28
AU2004233904A1 (en) 2004-11-11
KR101076059B1 (ko) 2011-10-21
AU2004233904B2 (en) 2009-11-12
CA2523740A1 (en) 2004-11-11
TNSN05275A1 (en) 2007-07-10
DK1617834T3 (da) 2007-02-05
SG160217A1 (en) 2010-04-29
EA013846B1 (ru) 2010-08-30
MY140382A (en) 2009-12-31
NO20055652D0 (no) 2005-11-30
PT1617834E (pt) 2007-01-31
EA200801073A1 (ru) 2008-08-29
KR20050119701A (ko) 2005-12-21
DE602004002585T2 (de) 2007-10-25
ES2274438T3 (es) 2007-05-16
US20080125488A1 (en) 2008-05-29
EP1759695A1 (en) 2007-03-07
CY1105880T1 (el) 2011-02-02
EP1617834B1 (en) 2006-09-27
JP5037937B2 (ja) 2012-10-03
CN1777416A (zh) 2006-05-24
TWI290045B (en) 2007-11-21
HK1085942A1 (en) 2006-09-08
MXPA05011532A (es) 2006-05-31
EP1617834A1 (en) 2006-01-25
DE602004002585D1 (de) 2006-11-09
ATE340568T1 (de) 2006-10-15
IL171721A (en) 2012-05-31
WO2004096204A1 (en) 2004-11-11
CA2523740C (en) 2012-05-15
PL1617834T3 (pl) 2007-02-28
JP2006525324A (ja) 2006-11-09
AR043670A1 (es) 2005-08-03
NZ543201A (en) 2007-05-31
ZA200509684B (en) 2007-03-28
CN1777416B (zh) 2012-11-07
TW200423923A (en) 2004-11-16
BRPI0409867A (pt) 2006-05-16
MA27845A1 (fr) 2006-04-03

Similar Documents

Publication Publication Date Title
NO20055652L (no) Laktatinneholdende farmasoytisk preparat og anvendelse av dette
AU2003275958A1 (en) Muteins of tear lipocalin
ATE496884T1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
HUP0401144A2 (hu) Enterális tápszerkészítmények
NO20052520L (no) Nye sulfamider
BRPI0504445A (pt) composição de trombina e processo para a sua preparação
DE10108900B4 (de) Ermittlung des patientenbezogenen Kariesrisikos
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
ATE494894T1 (de) Viruzide wirkungen von einer zubereitung enthaltend cetylpyridiniumchlorid und zitronensäure
AU2003273728A1 (en) A new crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid
ATE548043T1 (de) Polymorphe von 3-o-(3',3'- dimethylsuccinyl)betulinsäure-di-n-methyl-d- glucamin
WO2003086335A8 (en) Hair care composition for restoring the elasticity of hair
GB0511269D0 (en) Sustained release preparation of pro-insulin C-peptide
HUP0301864A2 (hu) Fenoláttartalmú, alacsony fagyáspontú készítmény
DE50312414D1 (de) Kompositmaterialien aus calciumverbindungen und glucuronsäurehaltigen polysacchariden
JP2006117574A (ja) 液体口腔用組成物
DK1409449T3 (da) Alpha-ketoglutarater af aktive ingredienser og sammensætninger omfattende disse
NO20061290L (no) Nye forbindelser
MY164917A (en) Lactate containing pharmaceutical composition and uses thereof
NO20004708L (no) Anvendelse av naturlig og/eller syntetisk kininsyre og/eller forlöpere derav som anti-insektsmiddel
MXPA05008860A (es) Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas.
ATE390934T1 (de) Aspirin enthaltende transdermale pharmazeutische zusammensetzung zur behandlung von verkalkung
TH104292B (th) องค์ประกอบของผลิตภัณฑ์ยาที่มีแลคเตตและแคลเซียมและการใช้องค์ประกอบดังกล่าว
TH104292A (th) องค์ประกอบของผลิตภัณฑ์ยาที่มีแลคเตตและแคลเซียมและการใช้องค์ประกอบดังกล่าว
TH89001A (th) ส่วนประกอบทางเภสัชกรรมที่มีแลคเตตและการใช้ส่วนประกอบดังกล่าว

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application